November 2010 Latest GI Updates from ESMO
Published: Mon Nov 1, 2010 Updated:Wed Sep 14, 2011We would like to thank Dr Scott Berry for the latest GI updates.
NORDIC VII Study: NORDIC FLOX given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer
HORIZON II: FOLFOX/XELOX +/- Cediranib for first-line treatment of metastatic colorectal cancer
HORIZON III: mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer
